Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.490 -0.050 (-0.76%)
Streaming Delayed Price Updated: 9:30 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
National Suicide Prevention Week Shines Light on Psychedelic Treatments
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Cardiff Oncology (NASDAQ: 
Via Benzinga
3 Biotech Stocks Wall Street Expects to Double Soon
All three stocks on this list can more than double your money according to investment bank analysts who cover them. 
Via The Motley Fool
Analyzing Compass Pathways's Unusual Options Activity
On Wednesday, shares of Compass Pathways (NASDAQ:CMPS) sa... 
Via Benzinga
Analyzing Compass Pathways's Unusual Options Activity
Shares of Compass Pathways (NASDAQ:CMPS) saw some unusual... 
Via Benzinga
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
Magic Mushroom Drug Stock Performances YTD
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Braxia Scientific Corp. (CSE:BRAX) (OTC: 
Via Benzinga
Open-Minded? Buy This Game-Changing Psychedelics Stock Now
Excellent investing opportunities frequently seem outlandish. 
Via The Motley Fool
Topics Supply Chain
Psychedelic Drug Patents: All Patents Are Not Created Equal
With many drug patenting opportunities in the emerging psychedelic drug industry, investors need to get up-to-speed on the different types of patents available -- and their strengths and weaknesses. 
Via Talk Markets
Topics Intellectual Property
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge
They're the first pioneers in exciting new markets. 
Via The Motley Fool
Compass Pathways Q2 Financials: Net Profit Down -38%; Stock Down -59% YTD
COMPASS Pathways plc reported its financial results for the Q2 ending June 30th, 2021, today, and gave an update on recent progress across its business. 
Via Talk Markets
Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary
Atai Life Sciences (NASDAQ:ATAI) has announced the launch ... 
Via Benzinga
COMPASS Pathways plc (CMPS) Q2 2021 Earnings Call Transcript
CMPS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know
Cybin (NYSE:CYBN), a biotech company in the psychedelics spa... 
Via Benzinga
Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022
Psychedelic stock headwinds are improving, and since Compass is at the forefront of psychedelic therapy, look for CMPS stock to take off soon. 
Via InvestorPlace
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange. 
Via Investor's Business Daily
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Understanding Compass Pathways's Unusual Options Activity
On Thursday, shares of Compass Pathways (NASDAQ:CMPS) saw unusual options activity. After the option alert, the stock price moved up to $38.2. Sentiment: NEUTRAL Option Type:... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.